THE GOG PARTNERS: PRACTICE CHANGING CERVICAL CANCER CLINICAL TRIALS
FROM RAMEZ ESKANDER, MD, UC SAN DIEGO & BHAVNA POTHURI, MD, NYU LANGONE

For patients with advanced stage or recurrence cervical cancer, clinical trials are critical to achieving better outcomes. In 2014, the results of a clinical trial, GOG-240, was a practice changing resulting in the United States FDA approval of bevacizumab in combination with chemotherapy for this patient population. Following this approval, continued interest in expanding treatment options for these patients with limited therapeutic alternatives following progression on a GOG-240 regimen catalyzed the design and completion of multiple clinical trials. These efforts have recently resulted in a dramatic transformation in the treatment landscape of recurrent cervical cancer, with 3 positive pivotal clinical trials.

The Empower-Cervical 1/GOG 3016/ENGOT-cx9 trial results were presented at the ESMO 2021 virtual plenary by Dr. Krishnansu Tewari and recently published (EMPOWER). This study was an open-label, phase 3, randomized (1:1), multi-center, trial of the anti-PD-1 drug cemiplimab versus investigators choice (IC) single agent chemotherapy in recurrent/metastatic cervical cancer that progressed after platinum-based therapy. This study represented the first positive phase 3 trial in the treatment of recurrent cervical cancer since the reporting of GOG-240. Six hundred eight patients were enrolled regardless of PD-L1 expression and randomized to receive either cemiplimab 350 mg IV every 3 weeks or investigator choice chemotherapy (pemetrexed, vinorelbine, gemcitabine, irinotecan or topotecan), up to 96 weeks; and were stratified by histology, squamous cell carcinoma (SCC), adenocarcinoma or adenosquamous (AC). The primary endpoint was overall survival.
(OS), which was analyzed in a hierarchical fashion first in patients with SCC followed by the total study population (SCC and AC). At the time of interim analysis, when 85% of events occurred among SCC patients, OS in SCC cohort was 11.1 months with cemiplimab versus 8.8 months with IC chemotherapy (HR 0.73 (CI: 0.58–0.91), P=0.003). In the total population, OS was 12 months with cemiplimab versus 8.5 months with IC chemotherapy (HR 0.73 (CI: 0.58–0.91), P < 0.001). In the context of these results, the trial was terminated early based on the unanimous recommendation of the IDMC, ultimately paving the way for FDA priority review of the supplemental Biologics License Application (sBLA) for cemiplimab in the treatment of patients with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy. The target action date for the FDA decision is January 30, 2022. Importantly, the sBLA is also being reviewed under the FDA’s Project Orbis initiative, which will allow for concurrent review by authorities in Australia, Brazil, Canada and Switzerland.

To read the full article, Click Here

The GOG Foundation, Inc. and GOG Partners is thrilled to present the “The GOG Highlight Reel”, an ongoing Education Series that will showcase clinical trials and other newsworthy education, from major medical meetings throughout the year.

This educational event will take place three times in a calendar year, with the first official highlight reel program presented virtually on Friday, November 19, 2021 from 2:30 pm - 5:00 pm EDT. The GOG Foundation, Inc. and GOG Partners will share a recap outlining major medical advancements in Gynecologic Oncology through discussion and presentation of the abstracts presented during some of the best oncology and women’s cancer meetings.

This engaging session will bring together the brightest minds and world-renown researchers. Didactic presentations, debates and expert panel discussions will have you and your colleagues on the edge of your seat, as our clinical experts share best practice and ways to improve the standard of care in gynecologic malignancies. The GOG Leadership will also present Trials In Progress.

Join us Friday, November 19, 2021 for the Fall 2021 GOG Highlight Reel session from 2:30 pm - 5:00 pm EST.

Click Here to Register Today!
The GOG Partners Program is currently recruiting for 20 clinical trials:

- 10 Ovary
- 4 Cervix
- 6 Endometrium

To search active trials visit our website by clicking "clinical trials" below.

CLINICAL TRIALS

The GOG Partners presents the “Accrual Culture: An Education Series on How to Build a Successful Clinical Trial Network.” This educational series provides mentorship and support for our new and established sites seeking to further improve their operations.

Our expert leaders will share their knowledge, experience and best practices to integrate into your clinical trial process.

To watch this exciting program, click the button below!

Accrual Culture

SPECIAL RECOGNITION

National Academy of Medicine Elects 100 New Members

The GOG Foundation, Inc. and GOG Partners would like to congratulate Anil Kumar Sood, MD, FACOG, FACS on his recent election to the National Academy of Medicine.

Dr. Sood's election is for discovering the mechanistic basis of effects of chronic stress on cancer and identifying the mechanisms of paraneoplastic thrombocytosis; developing among the first RNAi therapeutics and translating multiple new drugs from lab to clinic; and implementing a new care algorithm for advanced ovarian cancer, leading to substantially increased complete resection rates.

Click Here for the full list of 100 New NAM Members.

GOGF/AAOGF Mentored Physician-Scientist Award Winner

We are pleased to announce that Dr. R. Tyler Hillman from MD Anderson Cancer Center was awarded the
GOGF/AAOGF Mentored Physician-Scientist Award for his proposal entitled, “Liquid Biopsy Detection of Structural Variant Breakpoints to Monitor Ovarian Clonal Evolution.” The award is supported by GOG Foundation, AAOGF, and a generous grant from Clovis Oncology.

Congratulations Dr. Hillman!

GOG Foundation Board of Directors New Positions

On Thursday, July 22, 2021, The GOG Foundation, Inc. (GOG-F) Board of Directors met during the NRG July 2021 Semi-Annual Virtual Meeting. With unanimous votes, the board agreed to expand leadership and created new positions to attend to additional demands with an increased clinical trial portfolio. The GOG-F formally known as the Gynecologic Oncology Group has a 50-year history of successful research through clinical trials in women’s cancers.

The GOG-F is led by President, Dr. Larry J. Copeland, Professor at The Ohio State University, James Cancer Center. The new positions to the board of directors include Dr. Robert Mannel, Rainbolt Family Endowed Chair in Cancer and Professor of Gynecologic Oncology in the Department of Obstetrics and Gynecology at the University of Oklahoma Health Sciences Center (OUHSC) being elected to the newly created Senior Vice President Role for GOG-F and formerly serving as the GOG-F Vice president; Dr. Bradley Monk, Arizona Oncology, Creighton University/University of Arizona, formally as GOG-F Board Director at Large and Dr. Carol Aghajanian both appointed to GOG-F Vice President Roles to oversee the GOG Partners (GOG-P) and the NRG Oncology (NRG) clinical trial portfolios, respectively.

In addition to these recently created and integral roles, the GOG-F also appointed Dr. Tashanna Myers, Dr. David O’Malley and Dr. Brian Slomovitz as new board members-at-large and re-elected Dr. Paul DiSilvestro to a second term.

MARY “DICEY” SCROGGINS TRAVEL FUND

Mary “Dicey” Scroggins is a 25-year ovarian cancer survivor
and health activist who has made a significant impact to transforming the standard of care in gynecologic oncology by being the voice to patients.

For many years Dicey attended The GOG Board of Directors as an ex officio member representing the patient voice and guiding the GOG to better serve their patients. Most recently she served in a similar capacity of advocacy for URM for IGCS. The GOG will be forever grateful for the incredible impact Dicey for her service, engagement and cancer survivor perspective as the Chair of the Legacy GOG Patient Advocacy Committee.

To honor and continue Dicey’s legacy, the GOG is thrilled to announce the Mary “Dicey” Scroggins Travel Fund that will offer travel reimbursement for up to two patient advocates to attend the NRG Oncology 2022 Semiannual February Meeting and the GOG Foundation, Inc. meeting.

Application Deadline has been extended to November 15, 2021.

Click Here to apply!

GOG PARTNERS PAST EVENTS
ENDURING MATERIALS

Check out the GOG Past Events web page for on demand symposia recordings and meeting materials including the following recently added Independent Satellite Symposia:

- Targeting New Treatments in Cervical Cancer
- Emerging Immunotherapies & Novel Therapeutics in Endometrial Cancer

IIT LOI APPLICATION

Applications should be submitted electronically to the GOG by completing the online application.

Applications will be reviewed as they are submitted.

Please contact GOGPartners@gog.org with any related questions.

LET'S GET SOCIAL

What GOG Means to ME
The GOG Foundation, Inc. launched a “What GOG Means to ME” social media campaign and we would like you to participate.

As a participant in this campaign, you will be highlighted on our social media feeds (Twitter, Instagram, LinkedIn and Facebook). If you would like to participate, please email Lindsey Moeller at lmoeller@gog.org with no more than a 35-word quote.
indicating what GOG means to you. We will feature your quote along with the following information on our GOG Social Media platforms throughout the year.

- **Quote:** No more than 35 words indicating what GOG means to you, examples can include: research, clinical trials, networking.
- **Current Headshot (Jpg or PNG format)**
- **Current Title/Role**
- **Institution**
- **Social Tags:** Please provide how we can find you on each of the social platforms so we can tag you when we post.

We appreciate your participation!

**Become a GOG Social Media Agent**

The GOG Foundation is looking for members that are savvy with social media to become GOG Social Media Agents! Throughout the year our communications staff will invite our agents to participate in social media campaigns for meetings, education and special events. If you are interested in becoming a GOG Social Media Agent, please email Lindsey Moeller at lmoeller@gog.org and include the following information:

- Current Headshot (Jpg or PNG format)
- Current Title/Role
- Institution
- Social Tags

---

**How Can We Help?**

The GOG Partners Connection Quarterly Newsletter is produced by the GOG Foundation Communications Committee.

Please contact us at info@gog.org with any questions or suggestions regarding future content.